CDK4 and neoplasm: Combined inavolisib and CDK4/6 inhibition targets complementary tumor vulnerabilities—sustained PI3K signaling and aberrant cell-cycle progression—thereby addressing key resistance nodes and modulating the tumor microenvironment (Figure 3).